The need for unification of the guidelines for colorectal cancer - differences in the pathology organisations revealed
European Organisation for Research and Treatment of Cancer (EORTC) News Sep 16, 2017
Maria Urbanowicz, a young pathology fellow at the EORTC, presented her results of a survey comparing different guidelines for pathology reporting of colorectal cancer at the 29th European Congress of Pathology (ECP2017).
Urbanowicz reviewed and compared guidelines from Royal College of Pathologists (RCPath), Royal College of Pathologists of Australasia (RCPA), and College of American Pathologists (CAP). She then sent out a survey to 782 pathologists to find out what guidelines they followed in their routine practice and how they were implemented. 143 pathologists out of 30 countries responded to the survey.
She reported that there were differences in the colorectal cancer guidelines of the pathology organisations when it comes to: specimen handling, microscopic evaluation, staging and use of additional diagnostic techniques. She found that there was a variability in the implementation of the guidelines. For example, in the case of testing for mismatch repair proteins (MMR) or microsatellite instability (MSI), 30% always performed the testing, while 64 % sometimes and 1% never.
Urbanowicz states that there is a need for unification of the guidelines for colorectal cancer. She is cooperating with the International Collaboration on Cancer Reporting (ICCR), which consists of major pathology organisations and its aim is to produce internationally standardized and evidence based datasets for the pathology reporting of cancer.
ÂWe need to bring together the experts in pathology to produce common guidelines that can be used globally, she said. ÂCommon guidelines will make it easier to interpret pathology reports in any country and compare international data, which is especially important in clinical trials. It will benefit patients ensuring that they are given the same diagnosis and choice of treatment independent of the country. She concedes that it will not be easy given the disparities in healthcare across the world.
Maria Urbanowicz is gastrointestinal pathologist from Madrid who is following the ESP (European Society of Pathology)- EORTC training Fellowship in Translational Research (TR) at the European Organization of Research and Treatment of Cancer in Brussels. She applied for the fellowship as she wanted to learn more about clinical trials. ÂClinical research is important for pathologists. We are getting more involved in clinical trials, and hopefully we will lead more investigation projects, she said.
Go to Original
Urbanowicz reviewed and compared guidelines from Royal College of Pathologists (RCPath), Royal College of Pathologists of Australasia (RCPA), and College of American Pathologists (CAP). She then sent out a survey to 782 pathologists to find out what guidelines they followed in their routine practice and how they were implemented. 143 pathologists out of 30 countries responded to the survey.
She reported that there were differences in the colorectal cancer guidelines of the pathology organisations when it comes to: specimen handling, microscopic evaluation, staging and use of additional diagnostic techniques. She found that there was a variability in the implementation of the guidelines. For example, in the case of testing for mismatch repair proteins (MMR) or microsatellite instability (MSI), 30% always performed the testing, while 64 % sometimes and 1% never.
Urbanowicz states that there is a need for unification of the guidelines for colorectal cancer. She is cooperating with the International Collaboration on Cancer Reporting (ICCR), which consists of major pathology organisations and its aim is to produce internationally standardized and evidence based datasets for the pathology reporting of cancer.
ÂWe need to bring together the experts in pathology to produce common guidelines that can be used globally, she said. ÂCommon guidelines will make it easier to interpret pathology reports in any country and compare international data, which is especially important in clinical trials. It will benefit patients ensuring that they are given the same diagnosis and choice of treatment independent of the country. She concedes that it will not be easy given the disparities in healthcare across the world.
Maria Urbanowicz is gastrointestinal pathologist from Madrid who is following the ESP (European Society of Pathology)- EORTC training Fellowship in Translational Research (TR) at the European Organization of Research and Treatment of Cancer in Brussels. She applied for the fellowship as she wanted to learn more about clinical trials. ÂClinical research is important for pathologists. We are getting more involved in clinical trials, and hopefully we will lead more investigation projects, she said.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries